Abstract
Background and Objectives: To establish the feasibility of sentinel lymph node (SLN) identification in patients with stage IB1 invasive cervical cancer. Methods: Selected patients with cervical cancer scheduled for radical hysterectomy with bilateral pelvic lymphadenectomy underwent SLN detection. Preoperatively, 1 mCi of technetium-99 (99Tc) was injected into four points of the superficial cervical stroma around the tumor. Intraoperatively, the patients underwent gamma-probe-guided lymphatic mapping, and patent blue dye was injected into the same points as the 99Tc. Results: Of the 12 eligible patients, 11 (92%) had at least one SLN detected. Seven (64%) patients had SLNs detected by intraoperative lymphoscintigraphy and the blue-dye technique, 3 (27%) by intraoperative lymphoscintigraphy, and 1 (9%) by the blue-dye technique only. Intraoperatively, 22 SLNs were detected: 9 (41%) by lymphoscintigraphy, 7 (32%) by lymphoscintigraphy and the blue-dye technique, and 6 (27%) by the blue-dye technique only. Six patients (54.5%) had bilateral SLNs. Sensitivity, specificity, positive predictive value, and negative predictive value for SLN detection were 100%, 80%, 33%, and 100%, respectively. There were no false-negative results. Conclusions: In this small cohort of patients, the combination of 99Tc and patent blue dye was safe and feasible for the detection of SLNs in early-stage cervical cancer. This study investigates the sentinel lymph node technique in patients with stage IB1 cervical cancer.
Keywords: Sentinel lymph node (SLN), cervical cancer, patent blue dye, technetium
Current Cancer Therapy Reviews
Title: Sentinel Lymph Node Identification in Patients with Stage IB1 Invasive Cervical Carcinoma
Volume: 3 Issue: 3
Author(s): Ricardo dos Reis, Eduardo Belmonte Tavares, Beatriz Amaral, Heleusa Ione Monego, Marcia Binda, Valentino Magno, Waldemar Rivoire, Maria Isabel Edelweiss and Edison Capp
Affiliation:
Keywords: Sentinel lymph node (SLN), cervical cancer, patent blue dye, technetium
Abstract: Background and Objectives: To establish the feasibility of sentinel lymph node (SLN) identification in patients with stage IB1 invasive cervical cancer. Methods: Selected patients with cervical cancer scheduled for radical hysterectomy with bilateral pelvic lymphadenectomy underwent SLN detection. Preoperatively, 1 mCi of technetium-99 (99Tc) was injected into four points of the superficial cervical stroma around the tumor. Intraoperatively, the patients underwent gamma-probe-guided lymphatic mapping, and patent blue dye was injected into the same points as the 99Tc. Results: Of the 12 eligible patients, 11 (92%) had at least one SLN detected. Seven (64%) patients had SLNs detected by intraoperative lymphoscintigraphy and the blue-dye technique, 3 (27%) by intraoperative lymphoscintigraphy, and 1 (9%) by the blue-dye technique only. Intraoperatively, 22 SLNs were detected: 9 (41%) by lymphoscintigraphy, 7 (32%) by lymphoscintigraphy and the blue-dye technique, and 6 (27%) by the blue-dye technique only. Six patients (54.5%) had bilateral SLNs. Sensitivity, specificity, positive predictive value, and negative predictive value for SLN detection were 100%, 80%, 33%, and 100%, respectively. There were no false-negative results. Conclusions: In this small cohort of patients, the combination of 99Tc and patent blue dye was safe and feasible for the detection of SLNs in early-stage cervical cancer. This study investigates the sentinel lymph node technique in patients with stage IB1 cervical cancer.
Export Options
About this article
Cite this article as:
Ricardo dos Reis , Eduardo Belmonte Tavares , Beatriz Amaral , Heleusa Ione Monego , Marcia Binda , Valentino Magno , Waldemar Rivoire , Maria Isabel Edelweiss and Edison Capp , Sentinel Lymph Node Identification in Patients with Stage IB1 Invasive Cervical Carcinoma, Current Cancer Therapy Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339407781368332
DOI https://dx.doi.org/10.2174/157339407781368332 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Applications of Liposomal Based Drug Delivery and Drug Targeting for Immune Linked Inflammatory Maladies: A Contemporary View Point
Current Drug Targets Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets New Insights Toward Nanostructured Drug Delivery of Plant-Derived Polyphenol Compounds: Cancer Treatment and Gene Expression Profiles
Current Cancer Drug Targets Drug Delivery Systems with Modified Release for Systemic and Biophase Bioavailability
Current Clinical Pharmacology Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry Titanocenes as Anticancer Agents: Recent Insights
Medicinal Chemistry Surface Antigens/Receptors for Targeted Cancer Treatment: The GnRH Receptor / Binding Site for Targeted Adenocarcinoma Therapy
Current Cancer Drug Targets The Influence of AIDS on the Morphometric and Immune Status of the Uterine Cervix of Autopsied Patients
Current HIV Research The Adjunctive Value of Diffusion Weighted Imaging in Diagnosis and Follow Up of Uterovaginal Diffuse B-cell Lymphoma: A Case Report and Literature Review
Current Medical Imaging DNA Secondary Structure at Chromosomal Fragile Sites in Human Disease
Current Genomics Autophagy Regulators as Potential Cancer Therapeutic agents: A Review
Current Topics in Medicinal Chemistry The Use of Chronobiotics in the Resynchronization of the Sleep/Wake Cycle. Therapeutical Application in the Early Phases of Alzheimer's Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology Tapasin and Human Leukocyte Antigen Class I Dysregulation Correlates with Survival in Glioblastoma Multiforme
Anti-Cancer Agents in Medicinal Chemistry Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders
Mini-Reviews in Medicinal Chemistry Crocetin as an Active Secondary Metabolite of Saffron Stigma and Anticancer Effects
Current Cancer Therapy Reviews Purinergic (P2) Receptor Control of Lower Genitourinary Tract Function and New Avenues for Drug Action: An Overview
Current Pharmaceutical Design Pharmacological Potentials and Nutritional Values of Tropical and Subtropical Fruits of India: Emphasis on their Anticancer Bioactive Components
Recent Patents on Anti-Cancer Drug Discovery Tumor Angiogenesis: A Potential Target In Cancer Control by Phytochemicals
Current Cancer Drug Targets Stable Gastric Pentadecapeptide BPC 157-NO-system Relation
Current Pharmaceutical Design